• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sandoz to Pay Millions to CMS

Article

The fine is a result of the company falsifying sales price data to Medicare. In addition to the fine, Sandoz has to provide evidence that it has established a government pricing compliance program.

In what the federal government says is the largest such settlement ever reached, Sandoz has agreed to pay $12.64 million to resolve allegations that it misrepresented pricing data on medicines that were provided to the Centers for Medicare & Medicaid Services.

Sandoz, which is owned by Novartis and markets hundreds of generic drugs in the U.S., allegedly misrepresented the average sales price data to Medicare between January 2010 and March 2012, according to a statement from the Office of the Inspector General of the U.S. Department of Health & Human Services.

Complete post in The Wall Street Journal:

http://on.wsj.com/1bdPM92

Related Videos
Carrie Kozlowski
Carrie Kozlowski, OT, MBA
Carrie Kozlowski, OT, MBA
kimberly westrich
Bruce Sherman, MD
Dr Jeffrey Sippel
Lalan Wilfongd, MD, US Oncology Network
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.